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Abstract The G protein-coupled vasopressin V2 receptor (V2
receptor) contains a pair of conserved cysteine residues (C112
and C192) which are thought to form a disulfide bond between
the first and second extracellular loops. The conserved cysteine
residues were found to be important for the correct formation of
the ligand binding domain of some G protein-coupled receptors.
Here we have assessed the properties of the V2 receptor after
site-directed mutagenesis of its conserved cysteine residues in
transiently transfected human embryonic kidney (HEK 293)
cells. Mutant receptors (C112S, C112A and C192S, C192A)
were non-functional and located mostly in the cell’s interior. The
conserved cysteine residues of the V2 receptor are thus not only
important for the structure of the ligand binding domain but also
for efficient intracellular receptor transport. In addition to the
functional significance of the conserved cysteine residues, we
have also analyzed the defects of two mutant V2 receptors which
cause X-linked nephrogenic diabetes insipidus (NDI) by the
introduction of additional cysteine residues into the second
extracellular loop (mutants G185C, R202C). These mutations
are assumed to impair normal disulfide bond formation. Mutant
receptor G185C and R202C were efficiently transported to the
plasma membrane but were defective in ligand binding. Only in
the case of the mutant receptor R202C, the more sensitive
adenylyl cyclase activity assay revealed vasopressin-stimulated
cAMP formation with a 35-fold increased EC50 value and with a
reduced ECmax, indicating that ligand binding is not completely
abolished. Taking the unaffected intracellular transport of both
NDI-causing mutant receptors into account, our results indicate
that the observed impairment of ligand binding by the additional
cysteine residues is not due to the prevention of disulfide bond
formation between the conserved cysteine residues.
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1. Introduction
The antidiuretic action of the hormone arginine vasopressin
(AVP) in renal collecting duct epithelial cells is mediated by
the vasopressin V2 receptor, a member of the large family of
G protein-coupled receptors (GPCRs). Alignment of the pri-
mary sequences of GPCRs revealed that many contain a pair
of conserved cysteine residues, one in the ¢rst and the other in
the second extracellular loop. It is thought that these residues
are covalently linked by a disul¢de bond which ensures cor-
rect folding of these loops and, as a consequence, the estab-
lishment of the ligand binding domain. The requirement of
the disul¢de bond for ligand binding was demonstrated for
the m1 muscarinic acetylcholine receptor [1] and the gonado-
tropin releasing hormone (GnRH) receptor [2]. For the L2
adrenergic receptor, four extracellular cysteine residues (the
two conserved residues and two additional non-conserved
ones) were shown to be critical for high a⁄nity binding sites
[3]. Recent data indicate that two disul¢de bonds are formed,
surprisingly between conserved and non-conserved cysteine
residues in this receptor [4]. In contrast to the GPCRs de-
scribed above, the disul¢de bond between the conserved cys-
teine residues of rhodopsin seems not to be required for cor-
rect receptor folding [5].
The V2 receptor also contains the two conserved cysteine
residues (C112 and C192) in the ¢rst and second extracellular
loops, whose functional signi¢cance are not known. Here we
have assessed the properties of the receptor after site-directed
mutagenesis of these two residues. The investigation of the
putative disul¢de bond of the V2 receptor is of particular
interest since it may have clinical implications: mutations in
the gene of the V2 receptor cause X-linked nephrogenic dia-
betes insipidus (NDI) [6], a disease which is characterized by
the inability of the kidney to concentrate urine despite normal
or elevated levels of AVP. Interestingly, the majority of NDI-
causing mutations (review: [7]) in the second extracellular
loop introduce additional cysteine residues and may impair
receptor function by altering disul¢de bonding. Here we
have analyzed the defects of two NDI-causing mutations be-
longing to this group, namely the mutants G185C [8], and
R202C [8^10].
2. Materials and methods
2.1. Materials
Lipofectamine was purchased from Life Technologies (Eggenstein,
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Germany) and restriction enzymes from New England Biolabs
(Schwalbach, Germany). Trypan blue was from Seromed (Berlin,
Germany). The Quick Change site-directed mutagenesis kit was
from Stratagene (Heidelberg, Germany) and oligonucleotides from
Biotez (Berlin, Germany). [3H]AVP for the binding assay (64.8 Ci/
mmol) and [K-32P]ATP for the adenylyl cyclase assay (30 Ci/mmol)
were from NEN (Boston, MA, USA). All other reagents were from
Merck (Darmstadt, Germany). Plasmids pRCDN2, encoding the
wild-type V2 receptor cDNA [11], and plasmid pWT.GFP, encoding
a fusion of the red-shifted variant of the green £uorescent protein
(GFP) to residue K367 of the V2 receptor, were described previously
[12].
2.2. DNA manipulations
Standard protocols were used for DNA preparations and manipu-
lations. The nucleotide sequences of DNA fragments were veri¢ed
using the FS Dye Terminator kit from Perkin Elmer (Weiterstadt,
Germany).
2.3. Construction of mutant V2 receptors
Mutations C112S, C112A, C192S, C192A, G185C, and R202C
were introduced either by conventional PCR mutagenesis or by the
use of the Quick Change site-directed mutagenesis kit into the cDNA
of the untagged V2 receptor (plasmid pRCDN2 [11]) and of the GFP-
tagged V2 receptor (plasmid pWT.GFP [12]). Primer sequences were:
5P-GGCCAGATGCCCTGAGTCGGGCCGTG-3P (C112S, resulting
plasmids pC112S and pC112S.GFP); 5P-GGCCAGATGCCC-
TGGCTCGGGCCGTG-3P (C112A, resulting plasmids pC112A
and pC112A.GFP); 5P-GGGGTCACTGACAGCTGGGCCTGCT-
TTG-3P (C192S, resulting plasmids pC192S and pC192S.GFP); 5P-
GCGGGGTCACTGACGCCTGGGCCTGCTTTG-3P (C192A, re-
sulting plasmids pC192A and pC192A.GFP); 5P-GACTGCTGGGC-
CAGCTTTGCGGAGCC-3P (C195S, resulting plasmids pC195S and
pC195S.GFP); 5P-CAGCGCAACGTGGAATGCGGCAGCGGGG-
TCAC-3P (G185C, resulting plasmids pG185C and pG185C.GFP);
5P-CGGAGCCCTGGGGCTGTCGCACCTATGTC-3P (R202C, re-
sulting plasmids pR202C and pR202C.GFP).
2.4. Cell culture and transfection methods
HEK 293 cells were cultured at 5% CO2 in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing 10% heat-inactivated fetal bo-
vine serum, penicillin (100 U/ml) and streptomycin (100 Wg/ml). Cells
were grown on poly-L-lysine-coated plastic material to improve adher-
ence. Cells were transfected with lipofectamine according to the sup-
plier’s recommendations. For a 15 mm diameter well of a 24 well
plate, 5U104 HEK 293 cells were transfected with 250 ng plasmid
DNA and 2 Wl lipofectamine (for laser scanning microscopy lower
cell densities were used; see below). After removal of the transfection
reagent, cells were incubated for 48 h.
2.5. [3H]AVP binding assay and adenylyl cyclase assay
The [3H]AVP binding assay was carried out with intact, transiently
transfected HEK 293 cells as described previously for African green
monkey kidney (COS.M6) cells [11]. However, HEK 293 cells were
grown in 24 well plates (15 mm diameter/well) instead of the 35 mm
diameter dishes described for COS.M6 cells. The adenylyl cyclase
assay was carried out with nucleus-free crude membranes of transi-
ently transfected HEK 293 cells as described previously for stably
transfected Ltk3 cells [11].
2.6. Visualization of GFP-tagged receptors and cell surface staining in
living transiently transfected HEK 293 cells
HEK 293 cells (4U104) in a 35 mm diameter dish containing a
coverslip were transfected with 500 ng plasmid DNA and 7.5 Wl lipo-
fectamine according to the supplier’s recommendations. After removal
of the transfection reagent, cells were incubated for 48 h and the
coverslips with the adherent cells were washed twice with phos-
phate-bu¡ered saline (PBS, pH 7.0) and transferred immediately
into a self-made chamber (details on request). Cells were covered
with 1 ml PBS (pH 7.0), and GFP £uorescence was visualized on a
Zeiss 410 invert laser scanning microscope (Vexc = 488 nm, Vem = s 515
nm). Subsequently, the cell surface of the same cells was stained with
0.05% trypan blue as described [12]. Trypan blue £uorescence
(Vexc = 543 nm, Vem = s 590 nm) was recorded on a second channel
and overlap with the GFP signals was computed.
3. Results
3.1. Construction of mutant V2 receptors
To assess the signi¢cance of the conserved cysteine residues
for V2 receptor function, they were exchanged for serine res-
idues by site-directed mutagenesis yielding mutant receptors
C112S and C192S (Fig. 1). Since it was shown for rhodopsin
that replacement of the conserved cysteine residues by serine
residues may impair receptor folding and that this problem is
avoided by alanine substitutions [5], alanine replacements
were also constructed (mutant receptors C112A and
C192A). To analyze the defects of V2 receptor mutants caus-
ing X-linked NDI by the introduction of additional cysteine
residues in the second extracellular loop, mutant receptors
G185C and R202C (Fig. 1) were constructed.
3.2. Pharmacological properties of the mutant V2 receptors
To analyze the functional properties of the mutant V2 re-
ceptors, HEK 293 cells were transiently transfected and
[3H]AVP binding pro¢les to intact cells were recorded (Fig.
2). For the wild-type V2 receptor, a typical binding curve was
obtained with a KD of 4.6 nM, in agreement with numerous
previous reports. In contrast, no signi¢cant binding of
[3H]AVP to intact cells was detected when either of the con-
served cysteine residues was replaced by serine or alanine
residues (mutant receptors C112S, C112A, C192S and
C192A). The same was true for the two NDI-causing mutant
receptors G185C and R202C.
[3H]AVP binding to intact cells is not suited to detect func-
tional mutant receptors which are retained intracellularly.
Low a⁄nity binding sites at the cell surface may also not be
detected due to the limited sensitivity of the assay. Therefore,
total membrane fractions of transiently transfected HEK 293
cells were stimulated with AVP and adenylyl cyclase activity
assays were performed (Fig. 3). E⁄cient adenylyl cyclase stim-
Fig. 1. Topological model of the human V2 receptor. The one-letter
code for amino acids is used. The following putative post-transla-
tional modi¢cations are shown: glycosylation at asparagine 22, pal-
mitoylation at cysteine residues 341 and 342. The amino acid re-
placements for the conserved cysteine residues (C112S, C112A,
C192S, C192A) and for the two NDI-causing mutations (G185C,
R202C) are indicated. The putative disul¢de bridge is depicted be-
tween the conserved extracellular cysteine residues C112 and C192.
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ulation (EC50 = 1.9 nM) was only observed in membranes
containing the wild-type V2 receptor. For mutant receptor
R202C, AVP-sensitive adenylyl cyclase activity was detect-
able. However, the dose^response curve was right-shifted.
The EC50 value (65.3 nM) was about 35-fold higher than
that of the wild-type receptor. The ECmax was also reduced
(65% of wild-type). Low a⁄nity binding sites must thus be
present in the case of this mutant receptor. Adenylyl cyclase
stimulation was not detectable in membranes containing mu-
tant receptors C112S, C112A, C192S, C192A and G185C in-
dicating that these receptors were indeed not functional. Loss
of function may result from misfolding, i.e. from a gross al-
teration of the overall receptor structure, or from a more
de¢ned defect in a functional domain. Misfolded membrane
proteins are normally recognized by the quality control system
of the endoplasmic reticulum (ER) and, as a consequence, are
retained in the ER. Receptors with a more de¢ned defect in a
functional domain may, however, still be transport-compe-
tent. To assess these two possibilities, we have also analyzed
the intracellular transport of the mutant receptors.
3.3. Intracellular transport of the mutant receptors
We have previously shown that C-terminally GFP-tagged
V2 receptors exhibit pharmacological properties similar to
those of the untagged receptors and that these GFP fusions
are suited to localize mutant receptors in the cellular mem-
brane system [12]. Equivalent C-terminal GFP fusions were
constructed to analyze the intracellular transport of the mu-
tant receptors. Mutant receptors C112S.GFP, C112A.GFP,
C192S.GFP, C192A.GFP, G185C.GFP and R202C.GFP
were expressed in transiently transfected HEK 293 cells, and
the GFP £uorescence signals of the receptors were monitored
by laser scanning microscopy in living cells (Fig. 4, left panels,
in green). The cell surface of the same cells was identi¢ed by
the use of trypan blue (Fig. 4, central panels, in red; trypan
blue does not penetrate living cells and its auto£uorescence is
Fig. 2. Speci¢c [3H]AVP binding of intact, transiently transfected HEK 293 cells expressing wild-type and mutant V2 receptors. Left panel:
binding isotherm for cells expressing the wild-type V2 receptor. Data represent mean values of duplicates which di¡ered by less than 5%. The
binding isotherms of mutant receptors C112S, C112A, C192S, C192A, G185C and R202C overlapped the baseline and are thus not shown. For
clarity, speci¢c [3H]AVP binding of cells expressing these mutant receptors is shown in the right panel only at a saturating concentration (50
nM). Columns represent mean values of duplicates, which di¡ered by less than 5%. In all binding experiments, unspeci¢c binding contributed
up to 30% of total binding. Untransfected HEK 293 cells were used as a control. The results are representative of three individual experiments.
Fig. 3. Adenylyl cyclase activity assay with crude membranes of transiently transfected HEK 293 cells expressing wild-type and mutant V2 re-
ceptors. Left panel: AVP dose^response curves of membranes containing the wild-type receptor (WT) and mutant receptor R202C. Data repre-
sent mean values of two independent experiments each performed in duplicate. Duplicates di¡ered by less than 10%. The calculated EC50 values
were 1.9 nM (WT) and 65.3 nM (R202C). The dose^response curves of mutant receptors C112S, C112A, C192S, C192A and G185C over-
lapped the baseline and are thus not shown. For clarity, the adenylyl cyclase activity of membranes expressing these mutant receptors is shown
in the right panel only after maximal stimulation with 10 WM AVP. Columns represent mean values of two independent experiments each per-
formed in duplicate. Duplicates di¡ered by less than 10%. Untransfected HEK 293 cells were used as a control.
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suitable for visualizing the cell surface [12]). Computer overlay
of green GFP £uorescence and red trypan blue £uorescence
allows identi¢cation of receptors which are transported to the
cell surface (Fig. 4, right panels, colocalization is indicated by
yellow).
For the wild-type receptor (WT.GFP), GFP signals were
detected at the cell surface, as indicated by the substantial
overlap with the trypan blue signal. Additional GFP signals
were located inside the cells, presumably representing trans-
port intermediates en route to the cell surface or receptors
which are abundant as a consequence of overexpression. In
contrast, the GFP signals of the receptors carrying alanine
substitutions of the conserved extracellular cysteine residues
(C112A.GFP and C192A.GFP) were detected predominantly
intracellularly. The GFP signals di¡usely ¢lled the cell’s inte-
rior with the exception of the nucleus and only small amounts
were located at the cell surface, indicated by faint yellow
stains at the cell surface. For the mutant receptors carrying
the corresponding serine substitutions (C112S.GFP and
C192S.GFP), identical results were obtained (data not
shown). The conserved extracellular cysteine residues are
thus essential for the e⁄cient intracellular transport of the
V2 receptor. When the data obtained by the functional assays
([3H]AVP binding and adenylyl cyclase assay) are taken into
account, it is likely that the available cell surface receptors are
unable to bind the ligand and that the conserved extracellular
cysteine residues are thus also essential for ligand binding
similar as described for other GPCRs. [3H]AVP binding of
the wild-type V2 receptor was also sensitive to dithiothreitol
(data not shown), which is consistent with the view that di-
sul¢de bond formation is a prerequisite for a functional ligand
binding domain.
For the NDI-causing mutant receptors G185C.GFP and
R202C.GFP, the distribution of the GFP signals was equiv-
alent to that of WT.GFP, i.e. large amounts were detectable
at the cell surface, indicated by their overlap with the trypan
blue signal. These mutant receptors are thus transport-com-
petent and, taking the functional data into account, charac-
terized only by a ligand binding defect.
4. Discussion
We have shown here that the conserved extracellular cys-
teine residues in the ¢rst and second extracellular loops of the
V2 receptor are essential for the e⁄cient intracellular trans-
port and most likely also for the ligand binding properties of
the receptor. The signi¢cance of these residues for ligand
binding has also been reported for other GPCRs, namely
for the rat m1 muscarinic acetylcholine receptor [1] and the
GnRH receptor [2]. Similar results were obtained for the con-
served extracellular cysteine residues of the L2-adrenergic re-
ceptor, although these residues contribute to two disul¢de
bonds, each of which is formed between a conserved and a
non-conserved residue [4]. For all these GPCRs it was postu-
lated that connection of the ¢rst and second extracellular
loops by a disul¢de bond is a prerequisite for correct forma-
tion of the ligand binding domain. The same seems to be true
for the V2 receptor: although small portions of the mutant
receptors C112S, C112A, C192S and C192A were detectable
at the cell surface, the binding assay with intact cells and the
adenylyl cyclase assay with membranes did not reveal any
functional activity.
The reason why mutation of the conserved extracellular
cysteine residues led to receptors with an impaired cell surface
transport is not clear. The observed transport de¢ciencies may
result if the loss of the disul¢de bond causes receptor confor-
mations which provoke a prolonged association with the
chaperones of the quality control system of the ER (review:
[13]). It is unlikely that the conserved extracellular cysteine
residues and the putative disul¢de bond formed between
them contribute to a signal which allows sorting into trans-
port vesicles. Although these signals are likely to occur in
membrane proteins [14,15], they should be located in the cy-
toplasmic domains to interact with vesicular coat proteins
rather than in luminal (extracellular) domains, as is the case
for the conserved cysteine residues.
It was previously speculated that NDI-causing mutations
which lead to V2 receptors with additional extracellular cys-
teine residues may a¡ect the disul¢de bond of the V2 receptor
[8,16,17]. Here we show that two such mutations cause recep-
tor defects di¡erent from those observed for the receptors
with mutations of the conserved cysteine residues. This sug-
gests that the disul¢de bond between the two conserved cys-
teine residues may not be a¡ected by these two mutations.
The NDI-causing mutant receptor G185C was e⁄ciently
transported to the cell surface but was completely binding-
defective. A G185N substitution at this position did not a¡ect
AVP binding, demonstrating that the replaced residue G185
itself is not critical for the ligand binding properties of the V2
receptor [18]. It can be concluded that the observed ligand
binding defect results from the properties of the introduced
cysteine residue. An explanation which is consistent with the
preservation of the conserved disul¢de bond, but with a defect
resulting nevertheless from the properties of the introduced
cysteine residue, would be that the additional cysteine residue
forms a second disul¢de bond with the non-conserved residue
C195 of the second extracellular loop lying in the vicinity.
This additional bond may then impair ligand binding. This
hypothesis may also apply to some of the other NDI-causing
mutant receptors which have additional cysteine residues in
the second extracellular loop. For mutant receptor R202C,
however, the results can also be explained without the forma-
tion of an additional disul¢de bond (see below).
The NDI-causing mutant receptor R202C was previously
characterized by immuno£uorescence microscopy and
[3H]AVP binding assays as being transport-competent but
Fig. 4. Localization of GFP-tagged wild-type and mutant V2 receptors in living transiently transfected HEK 293 cells. Cells expressing the
wild-type V2 receptor (WT.GFP) and receptor mutants C112A.GFP, C192A.GFP, G185C.GFP and R202C.GFP were analyzed by confocal la-
ser scanning microscopy with horizontal (xy) scans. Receptor GFP £uorescence signals are shown in green (left panels) and cell surface trypan
blue signals of the same cells in red (central panels). GFP and trypan blue £uorescence signals were computer-overlaid (right panels; overlap is
indicated by yellow). GFP £uorescence is detectable only in the case of cells that were successfully transfected, whereas cell surface trypan blue
£uorescence is detectable for every cell present in the ¢eld of view. The scans show representative cells. Scale bar, 25 Wm. Similar data were ob-
tained in four independent experiments.
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binding-defective [10]. The ability of this mutant receptor to
couple to the Gs/adenylyl cyclase system was not determined
in this study. In agreement with this previous work, receptor
GFP £uorescence signals were observed at the cell surface and
we failed to detect speci¢c [3H]AVP binding sites. Using the
more sensitive adenylyl cyclase assay, however, we found that
this mutant receptor can activate the Gs/adenylyl cyclase sys-
tem, although the EC50 is increased 35-fold and the Emax is
reduced. In an extension to the previous study it can be con-
cluded that AVP binding is not completely abolished for this
mutant receptor. Furthermore, although it is clear that the
adenylyl cyclase assay is more sensitive than the [3H]AVP
binding assay, the extent of adenylyl cyclase stimulation
(Emax = 65% of wild-type) by the mutant receptor R202C is
surprising. Assuming a 35-fold decrease in ligand binding ac-
tivity (i.e. a decrease equivalent to the increase of the EC50),
speci¢c binding should be detectable for this mutant receptor,
at least when concentrations v50 nM [3H]AVP are used. A
low a⁄nity binding conformation may, in this case, be accom-
panied by a conformation which allows a more e⁄cient G
protein coupling.
As to the mechanism which might lead to the low a⁄nity
binding properties of mutant receptor R202C, recent data
indicating that residue R202 controls the ligand binding selec-
tivity of the rat vs. the human receptor are of particular in-
terest [18]. In the rat receptor, a leucine residue at this posi-
tion facilitates ligand binding whereas the arginine of the
human receptor is unfavorable. It was postulated that this
position is part of an exclusion mechanism, i.e. that it con-
stitutes a negative determinant which restricts ligand^receptor
interactions. Taking these data into account, the cysteine res-
idue of the R202C receptor mutation may simply strengthen
this negative determinancy and promote the exclusion further.
In addition to the formation of a second disul¢de bond, the
defect of mutant receptor R202C may thus also be explained
by the replacement of a residue which is directly relevant for
ligand binding.
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